Descripción del proyecto
Prevención de ictus con el teléfono inteligente
La fibrilación auricular (FA) es una enfermedad que causa una frecuencia cardíaca irregular y, a menudo, acelerada. Es el tipo más común de arritmia cardíaca sostenida y puede provocar un ictus, motivo por el que el diagnóstico precoz de la FA es importante. Sin embargo, los métodos de detección clásicos de la FA como el electrocardiograma (ECG) y el registro Holter durante veinticuatro horas tienen una tasa de éxito inferior al 20 %. En este contexto, el proyecto financiado con fondos europeos RedStroke está detrás de una nueva solución inteligente de tecnologías de la información y las comunicaciones para un cribado preciso y rentable de la FA, con el objetivo de prevenir los ictus basándose en las tecnologías presentes en un teléfono inteligente normal. En concreto, el cribado de la FA se podrá llevar a cabo con una precisión comparable a la del ECG, al instante y tan solo con un teléfono inteligente.
Objetivo
Stroke is the second most common cause of death and complex disability, accounting for ~1 million deaths in Europe each year. Total cost of stroke in the EU amounts to €65 billion a year. Main risk factor for stroke is atrial fibrillation (AF), the most common type of sustained cardiac arrhythmia. Early identification of AF can prevent strokes as treatment can be started on time. However, AF is difficult to capture and often not noticed. Classical AF detection methods (electrocardiogram [ECG] and 24 hour-holter-ECG) have less than 20% success rate. Plus these methods are costly and not suitable for routine large-scale screening. German SME company Preventicus developed a smart ICT solution for accurate and cost-efficient AF screening, aiming to prevent stroke, based on technologies present in a standard smartphone. Its technology is clinically proven in international studies (accuracy: 96%, predictive value: >99%). To ensure wide deployment as structured AF detection program, Preventicus has set-up clinical grade services surrounding its ‘core’ technology, e.g. Telecare service to verify AF suspects, to safeguard timely referral of the screened AF-patients to a cardiologist for AF confirmation and treatment initiation. The target market is an attractive high volume market (~150-200M end-users in Europe). Preventicus is the first European player in the market (all its competitors are US-based). As such, investments in the company will enhance Europe’s standing in the smart healthcare technologies market vis à vis the USA. Following successful commercialisation in Germany (~170,000 active users and sales to large health insurance companies), Preventicus is now ready to accelerate growth beyond Germany. Funding will allow the company to take the final steps needed for EU-wide roll-out, directly driving employment growth and profitability of the company (estimated cumulative revenues: €78 million in 2025, representing return of investment of >31 times the EIC grant)
Ámbito científico
- medical and health scienceshealth scienceshealth care serviceseHealth
- medical and health sciencesclinical medicinecardiologycardiovascular diseasescardiac arrhythmia
- medical and health scienceshealth sciencespublic health
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsmobile phones
- medical and health sciencesbasic medicineneurologystroke
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-2
Régimen de financiación
SME - SME instrumentCoordinador
07743 Jena
Alemania
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.